Neoadjuvant Enhertu and HER2-low breast cancer – Overall response rate of 75%
Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with Enhertu, trastuzumab deruxtecan, in the neoadjuvant setting had an overall response rate of 75% in the absence of anastrozole and 63% in combination with anastrozole.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
